While anti-cancer therapies, including chemotherapy, immunotherapy, radiotherapy, and targeted therapy, are constantly advancing, cardiovascular toxicity has become a major challenge for cardiologists and oncologists. This has led to an increasing demand of cardio-oncology units in Europe and a growing interest of clinicians and researchers. The Heart Failure 2019 meeting of the Heart Failure Association of the European Society of Cardiology in Athens has therefore created a scientific programme that included four dedicated sessions on the topic along with several additional lectures. The major points that were discussed at the congress included the implementation and delivery of a cardio-oncology service, the collaboration among cardio-oncology experts, and the risk stratification, prevention, and early recognition of cardiotoxicity. Furthermore, sessions addressed the numerous different anti-cancer therapies associated with cardiotoxic effects and provided guidance on how to treat cancer patients who develop cardiovascular disease before, during, and after treatment.

1st Department of Medicine Cardioangiology Faculty of Medicine University Hospital Hradec Králové Czech Republic

Comprehensive Heart Failure Center University Clinic Würzburg Würzburg Germany

Department of Cardiology and Pneumology Heart Center Göttingen German Center for Cardiovascular Medicine University of Göttingen Medical Center Georg August University Göttingen Germany

Department of Cardiology Lariboisière Hospital and U942 INSERM BIOCANVAS Paris University Paris France

Department of Cardiology Medical University of Vienna Vienna Austria

Department of Cardiology University of Groningen University Medical Center Groningen Groningen The Netherlands

Department of Community Cardiology Clalit Health Fund and Sackler Faculty of Medicine Tel Aviv University Tel Aviv Israel

Department of Internal Medicine American University of Beirut Medical Center Beirut Lebanon

Department of Translational Medical Sciences and Interdepartmental Center for Clinical and Translational Sciences Federico 2 University Naples Italy

Division of Cardiology and Metabolism Department of Cardiology Charité and Berlin Institute of Health Center for Regenerative Therapies partner site Berlin and Department of Cardiology Charité Campus Benjamin Franklin Berlin Germany

Faculty of Medicine and Heart Failure Center Belgrade University Medical Center University of Belgrade Belgrade Serbia

IRCCS San Raffaele Rome Italy

Royal Brompton Hospital and Imperial College London London UK

Sechenov Medical University Moscow Russia

University of Cyprus Medical School Nicosia Cyprus Department of Cardiology Cardio Oncology Clinic Heart Failure Unit Athens University Hospital 'Attikon' National and Kapodistrian University of Athens Athens Greece

000      

00000naa a2200000 a 4500

001      

bmc20025428

003      

CZ-PrNML

005      

20230131101321.0

007      

ta

008      

201125s2019 xxk f 000 0|eng||

009      

AR

024    7_

$a 10.1002/ehf2.12551 $2 doi

035    __

$a (PubMed)31884717

040    __

$a ABA008 $b cze $d ABA008 $e AACR2

041    0_

$a eng

044    __

$a xxk

100    1_

$a Anker, Markus S $u Division of Cardiology and Metabolism, Department of Cardiology, Charité and Berlin Institute of Health Center for Regenerative Therapies (BCRT) and DZHK (German Centre for Cardiovascular Research), partner site Berlin and Department of Cardiology, Charité Campus Benjamin Franklin, Berlin, Germany.

245    10

$a Recent advances in cardio-oncology: a report from the 'Heart Failure Association 2019 and World Congress on Acute Heart Failure 2019' / $c MS. Anker, S. Hadzibegovic, A. Lena, Y. Belenkov, J. Bergler-Klein, RA. de Boer, D. Farmakis, S. von Haehling, Z. Iakobishvili, C. Maack, R. Pudil, H. Skouri, A. Cohen-Solal, CG. Tocchetti, AJS. Coats, PM. Seferović, AR. Lyon, Heart Failure Association Cardio-Oncology Study Group of the European Society of Cardiology,

520    9_

$a While anti-cancer therapies, including chemotherapy, immunotherapy, radiotherapy, and targeted therapy, are constantly advancing, cardiovascular toxicity has become a major challenge for cardiologists and oncologists. This has led to an increasing demand of cardio-oncology units in Europe and a growing interest of clinicians and researchers. The Heart Failure 2019 meeting of the Heart Failure Association of the European Society of Cardiology in Athens has therefore created a scientific programme that included four dedicated sessions on the topic along with several additional lectures. The major points that were discussed at the congress included the implementation and delivery of a cardio-oncology service, the collaboration among cardio-oncology experts, and the risk stratification, prevention, and early recognition of cardiotoxicity. Furthermore, sessions addressed the numerous different anti-cancer therapies associated with cardiotoxic effects and provided guidance on how to treat cancer patients who develop cardiovascular disease before, during, and after treatment.

650    _2

$a kardiologie $x organizace a řízení $x trendy $7 D002309

650    12

$a kardiotoxicita $7 D066126

650    12

$a srdeční selhání $x komplikace $x patofyziologie $x terapie $7 D006333

650    _2

$a lidé $7 D006801

650    12

$a nádory $x komplikace $x patofyziologie $x terapie $7 D009369

655    _2

$a časopisecké články $7 D016428

700    1_

$a Hadzibegovic, Sara $u Division of Cardiology and Metabolism, Department of Cardiology, Charité and Berlin Institute of Health Center for Regenerative Therapies (BCRT) and DZHK (German Centre for Cardiovascular Research), partner site Berlin and Department of Cardiology, Charité Campus Benjamin Franklin, Berlin, Germany.

700    1_

$a Lena, Alessia $u Division of Cardiology and Metabolism, Department of Cardiology, Charité and Berlin Institute of Health Center for Regenerative Therapies (BCRT) and DZHK (German Centre for Cardiovascular Research), partner site Berlin and Department of Cardiology, Charité Campus Benjamin Franklin, Berlin, Germany.

700    1_

$a Belenkov, Yury $u Sechenov Medical University, Moscow, Russia.

700    1_

$a Bergler-Klein, Jutta $u Department of Cardiology, Medical University of Vienna, Vienna, Austria.

700    1_

$a de Boer, Rudolf A $u Department of Cardiology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands.

700    1_

$a Farmakis, Dimitrios $u University of Cyprus Medical School, Nicosia, Cyprus. Department of Cardiology, Cardio-Oncology Clinic, Heart Failure Unit, Athens University Hospital 'Attikon', National and Kapodistrian University of Athens, Athens, Greece. $7 xx0281405

700    1_

$a von Haehling, Stephan $u Department of Cardiology and Pneumology, Heart Center Göttingen, German Center for Cardiovascular Medicine (DZHK), University of Göttingen Medical Center, Georg-August-University, Göttingen, Germany.

700    1_

$a Iakobishvili, Zaza $u Department of Community Cardiology, Clalit Health Fund, and Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.

700    1_

$a Maack, Christoph $u Comprehensive Heart Failure Center (CHFC), University Clinic Würzburg, Würzburg, Germany.

700    1_

$a Pudil, Radek $u 1st Department of Medicine-Cardioangiology, Faculty of Medicine, University Hospital, Hradec Králové, Czech Republic.

700    1_

$a Skouri, Hadi $u Department of Internal Medicine, American University of Beirut Medical Center, Beirut, Lebanon.

700    1_

$a Cohen-Solal, Alain $u Department of Cardiology, Lariboisière Hospital and U942 INSERM, BIOCANVAS (Biomarqueurs Cardiovasculaires), Paris University, Paris, France.

700    1_

$a Tocchetti, Carlo G $u Department of Translational Medical Sciences and Interdepartmental Center for Clinical and Translational Sciences (CIRCET), Federico II University, Naples, Italy.

700    1_

$a Coats, Andrew J S $u IRCCS San Raffaele, Rome, Italy.

700    1_

$a Seferović, Petar M $u Faculty of Medicine and Heart Failure Center, Belgrade University Medical Center, University of Belgrade, Belgrade, Serbia.

700    1_

$a Lyon, Alexander R $u Royal Brompton Hospital and Imperial College London, London, UK.

710    2_

$a Heart Failure Association Cardio-Oncology Study Group of the European Society of Cardiology

773    0_

$w MED00197251 $t ESC heart failure $x 2055-5822 $g Roč. 6, č. 6 (2019), s. 1140-1148

856    41

$u https://pubmed.ncbi.nlm.nih.gov/31884717 $y Pubmed

910    __

$a ABA008 $b sig $c sign $y a $z 0

990    __

$a 20201125 $b ABA008

991    __

$a 20230131101318 $b ABA008

999    __

$a ok $b bmc $g 1599573 $s 1116114

BAS    __

$a 3

BAS    __

$a PreBMC

BMC    __

$a 2019 $b 6 $c 6 $d 1140-1148 $e 20191228 $i 2055-5822 $m ESC heart failure $n ESC Heart Fail $x MED00197251

LZP    __

$a Pubmed-20201125